Drug Profile


Alternative Names: IONIS-PKKRx; ISIS 546254; ISIS-PKKRx

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Migraine
  • Phase I Hereditary angioedema

Most Recent Events

  • 01 Aug 2017 Phase-II clinical trials in Migraine (Prevention) in USA (SC) (NCT03108469)
  • 17 Apr 2017 Ionis Pharmaceuticals plans a phase II study of IONIS PKKRx for Migraine (NCT03108469)
  • 27 Mar 2017 Preclinical trials in Migraine (Prevention) in USA (SC) (NCT03108469)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top